Prevention throughout the cardiovascular continuum

Prevention throughout the cardiovascular continuum demands a life‐course

strategy that addresses risk factors, organs and clinical syndromes as a single,

connected pathway—from obesity, diabetes and dyslipidaemia to vascular

inflammation, hypertension, angina, heart failure and cardiorenal disease.

This Menarini Foundation course brings together an international faculty to

review state‐of‐the‐art science and practical therapies at every step of that

pathway, including GLP‐1 receptor agonists and SGLT2 inhibitors, advanced

lipid‐lowering strategies for LDL‐C, Lp(a) and triglyceride‐rich lipoproteins,

as well as PCSK9‐targeted and other emerging oral agents, and novel

anti‐inflammatory approaches to atherosclerosis. Through focused sessions on

obesity/diabetes, lipids, inflammation, hypertension, angina, heart failure and

the cardiorenal axis, the programme will address the management of high‐risk

phenotypes commonly seen in practice—such as patients with combined CAD,

HF, CKD, obesity or diabetes—and provide case‐based guidance on how to

sequence and combine therapies to reduce residual risk. Finally, participants

will explore how emerging tools in personalised medicine, including AI‐enabled

decision support, coronary CT imaging, contemporary clinical risk scores (e.g.

SCORE2 and SMART2) and polygenic risk scores, can refine cardiovascular risk

prediction, support shared decision‐making and help deliver truly individualised

prevention strategies in everyday clinical care.

Co-Presidents of the Congress

Giuseppe Rosano
Camafort Miquel
Mostaza Prieto José Maria